
Supplementary information


The changing landscape of cancer cell therapies: clinical trials and real-world data

In the format provided by the authors and unedited

Supplementary Figure 1: Global landscape of cell therapy clinical trials: 5,639 interventional trials in record (data cut-off: March 2024).



Supplementary Figure 2: Global landscape of cell therapy clinical trials: 2,692 unique cell therapy products in record (data cut-off: March 2024).





Supplementary Figure 3:

Α.

Β.

Clinical trials with FDA-approved CAR-Ts or TIL, by status






Supplementary Figure 4:


A. Cell therapy trials by sponsor type.


	3,650 64.73%						1,989 35.27%				5,639	Sponsor Type Company		
0	500	1000	1500	2000	2500	3000	3500	4000	4500	5000	5500	6000		


B. Cell therapy trials, by phase, sponsor type, and trial start year.




 Cell therapy trials by trial start year and indication (% indicates year-toyear growth)









Supplementary Figure 6: Cell therapy modalities in oncology clinical trials by indication type and trial start date (% indicates year-to-year growth)



Supplementary Figure 7: Cell therapy modalities in oncology clinical trials by tumor type and trial start date (% indicates year-to-year growth).




Supplementary Figure 8:



A. Cell therapy trials by trial start year and cell source (% indicates year-to-year growth)

B. CAR-T cell therapy trials by trial start year and cell source (% indicates year-to-year growth)




Supplementary Figure 9: Top 15 targets of cell therapy modalities in oncology clinical trials by trial start date.


		Nr. Clinical Trials	Year-over- year difference						
CD19	2021	104		CD19	2021	8	95	5	
	2022	104	0.0%		2022	9	95	5	
	2023	88	-15.4%		2023	5	82		
всма	2021	39		BCMA	2021	37			
	2022	27	-30.8%		2022	24			
	2023	26	-3.7%		2023	23			
CD22	2021	16		CD22	2021	16			
	2022	20	25.0%		2022	19			
	2023	8	-60.0%		2023	8			
MSLN	2021	12		MSLN	2021	10			
	2022	18	50.0%		2022	14			
	2023	12	-33.3%		2023	11			
CD7	2021	19		CD7	2021	19			
	2022	9	-52.6%		2022	9			
	2023	12	33.3%		2023	12			
CD33	2021	10		CD33	2021	9			
	2022	11	10.0%		2022	11			
	2023	6	-45.5%		2023	5			
HER2	2021	10		HER2	2021	4			
	2022	7	-30.0%		2022	4 3			
	2023	8	14.3%		2023	33			
GPC3	2021	10		GPC3	2021	9			
	2022	11	10.0%		2022	8			
	2023	5	-54.5%		2023	3			
CLDN18	2021	8		CLDN18	2021	7			
	2022	10	25.0%		2022	9			
	2023	10	0.0%		2023	9			
B7H3	2021	9		B7H3	2021	9			
	2022	12	33.3%		2022	12			
	2023	5	-58.3%		2023	5			
NKG2D	2021	8		NKG2D	2021	7			
	2022	3	-62.5%		2022	2			
	2023	10	233.3%		2023	7			
CD70	2021	5		CD70	2021	5			
	2022	8	60.0%		2022	7			
	2023	9	12.5%		2023	7			
GPRC5D	2021	3		GPRC5D	2021	3		CT modality	
	2022	4	33.3%		2022	4		CAR-T cells	
	2023	8	100.0%		2023	8			
IL15(R)	2021	3		IL15(R)	2021			Other T cells	
	2022	5	66.7%		2022			Cell-based CV	/s
	2023	7	40.0%		2023	4		CAR-NK cells	
NY-ESO-1	2021	2		NY-ESO-1	2021			Other CTs	
	2022	7	250.0%		2022	6		Undisclosed (CT two
	2023	4	-42.9%		2023	2			стсур

Nr of clinical trials incorporating each target/modality


A. Targets of cell therapies, by trial start year.



B. Number of different cell therapy targets in oncology clinical trials, by trial start date (2010-2023 only).



Supplementary Figure 11: Targets of main cell therapy modalities in oncology clinical trials, by clinical trial start year.




Supplementary Figure 12: IQVIA CAR-T Cell Center Insights – Q4 2023 Survey.

04'23 (% Oncologists, n=52) 54% 54% 63% 63% Not collected 65% Not collected 0
54% 63% Not collected 65% Not collected
63% Not collected 65% Not collected
Not collected 65% Not collected
65% Not collected
Not collected
31%
27%
Not collected

Question 1. If there are patients who were initially considered for CAR T-Cell therapy but did not receive it finally, what were the reasons for that? Please select all that apply. Question 2. Can you please share the main reason that patients decide not to receive CAR T-Cell therapy? Source: CAR T-Cell Monitor - Center Insights

#New option added Survey fielded January 1 - January 23, 2024

Supplementary Figure 13




Number of US CAR-T centers by year

Year	Nr. of center in USA	Year-over- year growth
2023	198	+ 9.39 %
2022	181	+11.04 %
2021	163	+19.85 %
2020	136	+21.42 %
2019	112	+27.27 %
2018	88	


Question: What CAR T-Cell treatment center do you refer your patients to? Use the hierarchical list below to select the facility/institution or select "Other" if you cannot locate it. Source: CAR T-Cell Monitor - Referral Insights

Survey fielded January 3 - January 24, 2024

Supplementary Figure 14: Number of oncology cell therapy deals by type and share of all life sciences deals, 2014-2023.



Supplementary Figure 15: Clinical trials testing gene-modified cell therapies in autoimmune disorders, by trial start date (Source: GlobalData, May 2024).



Supplementary Methods:

Dataset and analysis

The data on cell therapy in oncology clinical trials were collected from GlobalData's Trial Database and subsequently curated by Cancer Research Institute (CRI) based on CRI IO Analytics definition of different immunotherapy types and drug target information. The data cut-off is March 2024. Cell therapy trials in autoimmune disorders were sourced from GlobalData's Trial Database with cut-off date of May 2024.

Cell therapies were classified into 9 main modalities based on the cell type and mechanisms of action being leveraged: (1) CAR-T cells, (2) Other T cells, (3) Cell-based Cancer Vaccines, (4) CAR-NK cells, (5) Other NK cells, (6) Bacteria, (7) Stem cells, (8) Other cell types and (9) Undisclosed cell therapy type. The "Other T cells" category has been further divided into subcategories attending to available information of these assets: Gama/delta TCR T-cells, TCR T-cells, Tumor Infiltrating Lymphocytes (TILs) and Other/Unspecified T-cells.

Cancer type classification by body location/system was done following the National Cancer Institute guidelines: https://www.cancer.gov/types/by-body-location

Real-world data on barriers to CAR-T cell treatment was obtained from IQVIA proprietary database "CAR T-Cell Monitor" (Center Insights and Referral Insights). This database provides insights on the patient journey from the referring oncologists to the advanced treatment centers that administer these therapies. This global syndicated study provides quantitative data on key touchpoints along this continuum. The U.S. data sources are quarterly primary research (Treatment module: n=51 Oncologists, Referring module: n=100 Oncologists) and publicly available data (sales, pricing, centers). In Supplementary Figure 12, Q4 2023 Survey data was compared with Q4 2021 Survey results presented in https://doi.org/10.1038/d41573-022-00095-1, which were collected by IQVIA using comparable methods.

Data on oncology cell therapy deals between 2014 and 2023 was obtained from IQVIA proprietary database "IQVIA Pharma Deals" as of January 2024.

Analyses, tables and graphical representations were done by using Tableau, except for tables and graphical representations in Supplementary Figure 12, 13 and 14, which were generated with Power Point.